Single-station skip-N2 disease: good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease)

被引:18
|
作者
Yazgan, Serkan [1 ]
Ucvet, Ahmet [1 ]
Gursoy, Soner [1 ]
Samancilar, Ozgur [1 ]
Yagci, Tarik [1 ]
机构
[1] Univ Hlth Sci, Dr Suat Seren Chest Dis & Surg, Med Practice & Res Ctr, Dept Thorac Surg, Izmir, Turkey
关键词
Non-small-cell lung cancer; Lymph node; Metastasis; MEDIASTINAL LYMPH-NODES; NEOADJUVANT CHEMOTHERAPY; PRIMARY TUMOR; N2; DISEASE; STAGE; METASTASIS; SURVIVAL; SURGERY; CARCINOMAS;
D O I
10.1093/icvts/ivy244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Pathological N2 (pN2) involvement has a negative impact on prognosis in patients operated on due to non-small-cell lung cancer (NSCLC). pN2 disease may cause skip (pN0N2) or non-skip (pN1N2) metastases with pathological N1 (pN1) involvement. The effect of pN2 subgroups on prognosis is still controversial. We analysed the effect of pN1 disease and single-station pN2 disease subgroups on survival outcomes. METHODS The medical records of patients who underwent anatomical lung resection due to NSCLC at a single centre between January 2007 and January 2017 were prospectively collected and retrospectively analysed. Operative mortality, sublobar resection, Stage IV disease, incomplete resection and carcinoid tumour were considered exclusion criteria. After histopathological examination, the prognosis of patients with pN1, pN0N2 and pN1N2 was compared statistically. Univariable and multivariable analyses were made to define independent risk factors for overall survival rates. RESULTS The mean follow-up time for 358 patients with 228 pN1 disease (63.7%), 59 pN0N2 disease (16.5%) and 71 pN1N2 disease (19.8%) was 40.430.4months. Median and 5-year overall survival rates for pN1, pN0N2 and pN1N2 diseases were 73.6months [95% confidence interval (CI) 55.5-91.7] and 54.1%, 60.3months (95% CI 26.8-93.8) and 51.2%, 20.8months (95% CI 16.1-25.5) and 21.5%, respectively. The survival CIs of pN1 and pN0N2 diseases were similar, and the survival rates of these 2 groups were significantly better than those with pN1N2 (P<0.001, P=0.001, respectively). In multivariable analysis, patients over the age of 60 [hazard ratio (HR) 2.13, P<0.001], patients not receiving adjuvant therapy (HR 1.52, P=0.01) and patients with pN1N2 disease (HR 2.91, P<0.001) had a poor prognosis. CONCLUSIONS Advanced age, not receiving adjuvant therapy and having pN1N2 disease are negative prognostic factors in patients with nodal involvement who underwent curative resection due to NSCLC. The overall survival and recurrence-free survival rates of pN1 disease and single-station pN0N2 disease are similar, and they have significantly better survival rates than pN1N2 disease. Based on these results, surgical treatment may be considered an appropriate choice in patients with histopathologically diagnosed single-station skip-N2 disease.
引用
收藏
页码:247 / 252
页数:6
相关论文
共 50 条
  • [31] Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer
    Komatsu, Hiroaki
    Mizuguchi, Shinjiro
    Izumi, Nobuhiro
    Chung, Kyukwang
    Hanada, Shoji
    Inoue, Hidetoshi
    Suehiro, Shigefumi
    Nishiyama, Noritoshi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
  • [32] Long-Term Survival Effect of the Interval between Postoperative Chemotherapy and Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small-Cell Lung Cancer
    Lin, Shih-Min
    Ku, Hsiu-Ying
    Hsu, Che-Yu
    Wang, Chih-Liang
    Chang, Gee-Chen
    Chang, Cheng-Shyong
    Liu, Tsang-Wu
    CANCERS, 2021, 13 (10)
  • [33] Long-Term Outcomes of Selected Patients with IIIA-N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection
    Fu, Fangqiu
    Sun, Wenrui
    Bai, Jinsong
    Deng, Chaoqiang
    Zheng, Difang
    Li, Yuan
    Zhang, Yang
    Chen, Haiquan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (13) : 8261 - 8270
  • [34] LONG-TERM SURVIVAL OF PATIENTS WITH CN2/PN2 NON-SMALL-CELL LUNG CANCER
    Jheon, Sanghoon
    Yi, Eunjue
    Kim, Kwhanmien
    Cho, Sukki
    Yang, Hee Chul
    Seok, Yangki
    Noh, Dongsub
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S517 - S517
  • [35] Is single-station N2 disease on PET-CT an indication for primary surgery in lung cancer patients?
    Kowalewski, Janusz
    Szczesny, Tomasz J.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (12) : 4828 - 4831
  • [36] Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer
    Tanaka, F
    Yanagihara, K
    Otake, Y
    Kawano, Y
    Miyahara, R
    Takenaka, K
    Katakura, H
    Ishikawa, S
    Ito, H
    Wada, H
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (06) : 612 - 618
  • [37] Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer
    Fumihiro Tanaka
    Kazuhiro Yanagihara
    Yosuke Otake
    Yozo Kawano
    Ryo Miyahara
    Kazumasa Takenaka
    Hiromichi Katakura
    Shinya Ishikawa
    Harumi Ito
    Hiromi Wada
    Annals of Surgical Oncology, 2004, 11 : 612 - 618
  • [38] Surgical Resection of Non-Small Cell Lung Cancer with N2 Disease
    Donington, Jessica S.
    Pass, Harvey I.
    THORACIC SURGERY CLINICS, 2014, 24 (04) : 449 - +
  • [39] Multimodality Treatment With Surgery for Locally Advanced Non-Small-Cell Lung Cancer With N2 Disease: A Review Article
    Toyokawa, Gouji
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    CLINICAL LUNG CANCER, 2015, 16 (01) : 6 - 14
  • [40] Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
    Qiao, Rong
    Zhong, Runbo
    Xu, Jianlin
    Zhang, Yanwei
    Zhang, Bo
    Wang, Shuyuan
    Lou, Yuqing
    Chen, Dongfang
    Chang, Qing
    Zhao, Yizhuo
    Han, Baohui
    JOURNAL OF CARDIOTHORACIC SURGERY, 2019, 14 (1)